Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
- Chamber
- Senate
- Introduced
- Mar 24, 2025
- Last action
- May 29, 2026 — REFERRED TO HEALTH
- Session
- 2025-2026
- Momentum
- 66 · High